Ex vivo method for increasing and maintaining the cytotoxic capacity of natural killer (NK) cells

WO2026236861A1PCT designated stage Publication Date: 2026-11-19UNIV DE SANTIAGO DE CHILE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/CL2026/050078
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2026-03-31
Filing Date
2026-05-14
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Current adoptive cell therapies using NK cells face challenges in maintaining their cytotoxic capacity and IFNγ release over time due to immunosuppressive tumor microenvironments, limiting their effectiveness in cancer treatment.

Method used

A two-phase activation and expansion method for NK cells involving the use of an ectonucleotidase inhibitor, such as CD39, followed by sequential cytokine stimulation with IL-2 and IL-15, enhances mitochondrial metabolism and maintains high cytotoxic activity and IFNγ secretion.

Benefits of technology

The method results in NK cells with sustained cytotoxic capacity and increased IFNγ release, optimizing their antitumor functionality ex vivo for extended periods.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000019_0001_TABLE
    Figure IMGF000019_0001_TABLE
  • Figure 00000031_0000
    Figure 00000031_0000
  • Figure 00000031_0001
    Figure 00000031_0001
Patent Text Reader

Abstract

The present invention relates to an ex vivo method designed to treat natural killer (NK) cells with the aim of enhancing their functionality, in particular their cytotoxic capacity and interferon-gamma release, wherein this cytotoxic capacity is also maintained for a longer period in the activated cells. Furthermore, the invention relates to NK cells that are activated using this method and which demonstrate optimised ex vivo anti-tumour activity, owing to their improved cytotoxic capacity and interferon-gamma release, and also to their use in the treatment and prevention of infectious diseases, autoimmune diseases and cancer, or as a preventative measure for the elimination of senescent cells from the body.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] “EX VIVO” METHOD TO INCREASE AND MAINTAIN THE CYTOTOXIC CAPACITY OF NATURAL KILLER (NK) CELLS

[0002] FIELD OF INVENTION

[0003] This application relates to an ex vivo method for treating Natural Killer (NK) cells to enhance their functionality, particularly their cytotoxic capacity and IFNγ release, where this cytotoxic capacity is also maintained for a longer period in the activated cells. Furthermore, the invention relates to NK cells activated by this method that exhibit optimized antitumor capacity ex vivo, by improving their cytotoxic capacity and IFNγ release.

[0004] BACKGROUND OF THE INVENTION

[0005] Cancer is a disease characterized by the uncontrolled proliferation of transformed cells that can invade adjacent tissues and spread to other parts of the body (metastasis). Its development is normally controlled by the immune system in a process known as immunosurveillance. However, transformed cells are known to have the ability to evade immune recognition or inhibit immune activity, allowing them to grow and proliferate faster than the immune system can control. At this point, the mass of transformed cells begins to drive cancer development, creating a tumor microenvironment (TME) that further hinders the immune system's ability to efficiently eliminate these cells.

[0006] The TME is formed by cancer cells surrounded by various types of non-malignant cells, immersed in an altered and vascularized extracellular matrix. In this microenvironment, the TME, there is an increased expression of enzymes and secreted molecules that support immune evasion by tumors, such as IL-10, TGF-β3, Reactive Oxygen Species (ROS), NOS, and arginase 1, as well as immune checkpoint molecules like PD-L1, which inhibit T cells and Natural Killer (NK) cells. These, along with the secretion of inflammatory mediators such as IL-1β3, TNF-α, and IL-6, promote tumor growth and progression.

[0007] Advances in knowledge about the immune system have accelerated the development and positioning of immunotherapies as first-line therapies for cancer treatment, including the use of antibodies that inhibit immune checkpoints (e.g., CTLA 4 and PD-1), the administration of specific cytokines, or adoptive cell therapies using T lymphocytes or NK cells [Waldman, 2020; Piccinelli, 2023]. However, immunotherapies have shown limitations in their effectiveness due to the high immunosuppression of the TME and the low immunogenicity of cancer cells.

[0008] In addition to immune checkpoints, in TME there is also a wide variety of factors that change the metabolism of immune system cells, favoring differentiation towards regulatory phenotypes and decreasing the function of cells with antitumor function [Kouidhi, 2019]; therefore, intervening in the mechanisms that metabolically reduce immunity, or promoting the development of metabolic phenotypes of immune cells that allow them to resist and compete in TME, is crucial to generating an effective anticancer therapy.

[0009] In recent decades, adoptive cell therapies using cytotoxic T lymphocytes have achieved significant and effective advances in cancer treatment [Marofi, 2021; Piccinelli, 2023]. Adoptive therapies using NK cells have shown promising results in clinical trials for a variety of solid and hematologic malignancies, in some cases achieving complete remission. Furthermore, NK cell therapies have demonstrated a superior safety profile and fewer toxicity issues compared to therapies using T cells or chimeric antigen receptor T cells (CAR-T cells) [Piccinelli, 2023]. Although NK cells have shown good results in cancer therapy, their full potential has been limited by TME (transcutaneous electrical nerve maturation).To overcome these limitations, various protocols have been developed to optimize different characteristics of NK cells before adoptive transfer, including genetic engineering modification (CAR-NK), cytokine stimulation, and combination therapies [Page, 2024].

[0010] Furthermore, NK cells can recognize and eliminate both virus-infected cells and tumor cells, as they possess spontaneous cytotoxic activity that does not require prior activation, and they can produce cytokines when activated by other cytokines or through the recognition of target cells. Unlike T lymphocytes, NK cell activation is not restricted by antigen presentation via the major histocompatibility complex class I (MHC-I).

[0011] Once the target cell is recognized by NK cells, the process of cell death begins with the formation of the immunological synapse. Adhesion molecules (e.g., integrins) participate in this process, triggering calcium influxes (intracellular signals) that contribute to the mobilization of cytotoxic granules toward the synapse and their subsequent fusion with the membrane, releasing their contents into the synoptic cleft. The cytotoxic granules of NK cells are specialized lysosomal vesicles loaded with proteins (perforin and granzymes), whose secretion mediates the cytotoxicity of these cells. Perforin is a glycoprotein (~70 kDa) that, when released into the synoptic space, forms oligomesh, creating pores in the target cell membrane. Granzymes (proteases) enter through these pores, leading to cell death.

[0012] The granzyme family comprises five members in humans and ten in mice, of which granzymes A and B (GzmA, GzmB) are the most abundant and best studied in both species. GzmB has the ability to activate caspases and other apoptogenic molecules, primarily inducing cell death through this mechanism. However, it is now known that molecules contained in the cytotoxic granules of NK cells can also induce necrosis or pyroptosis, triggering a pro-inflammatory response and thus activating an adaptive immune response that favors the elimination of tumor cells. In addition to perforin- and granzyme-mediated cell death, NK cells can generate cytotoxicity through the activation of death receptors on the target cell.The potent secretory function of NK cells allows them to release pro-inflammatory cytokines, such as IFN-γ, TNF-α, and GM-CSF, in response to stimulation by cytokines such as IL-2 and IL-15, among others [Topham, 2009; Fauhat, 2010]. Of these cytokines, IFN-γ is fundamental for mounting an adequate immune response because it strengthens innate immunity and promotes the generation of a potent adaptive immune response. On the one hand, it stimulates the maturation and activation of dendritic cells, increasing the expression of MHC II molecules, and on the other hand, it modulates the adaptive immune response, favoring Th1 and Th2 responses, which are dependent on IFN-γ levels in the environment [Scott, 1991]. In addition, NK cells release chemokines such as MIP1α, RANTES, and IL-8, which can activate and attract other cell types.This, along with the release of antigens produced by their cytotoxic activity, which can then be presented to T lymphocytes, makes NK cells key players in generating an effective immune response. Therefore, the use of NK cells for antitumor therapies offers significant advantages in terms of safety, direct cytotoxic activity, and their role in the development of the adaptive immune response.

[0013] Adoptive cell therapies using cytotoxic lymphocytes have made significant progress in cancer treatment. This type of therapy involves the ex vivo expansion and / or modification of autologous immune cells, from peripheral blood or tumor tissue, to enhance their anticancer activity. These expanded and / or modified cells are then infused into patients to mediate tumor regression [Du, 2023; Yuwen, 2024], providing a sufficient number of effector cells with modifiable functions and long-lasting responses.

[0014] CAR-NK cell therapies have shown promising results in both hematologic cancers and clinically advanced or extensively metastatic solid tumors where conventional and / or surgical treatments have shown poor responses [Wang, 2024; Sara, 2023]. However, although several phase I, II, and III clinical trials using NK or CAR-NK cells exist [Sara, 2023], these therapies continue to face challenges, particularly regarding their ability to infiltrate tumors and maintain activity and survival in the tumor management unit (TMU). Developments have been made to improve these therapies using various strategies, such as cytokine combinations. It is important to consider that, while these cells do not require prior activation to recognize and eliminate tumor cells, their activity can be enhanced by cytokines.Thus, it has been shown that NK-92 cells modified to co-express IL-15 bound to its high-affinity receptor (IL-15Ra) have greater secretion of pro-inflammatory cytokines and cytotoxic activity against cancer cell lines in vitro and in vivo model [Silvestre, 2023].

[0015] US patent document US2015072425 discloses, among other things, a method for producing a population of activated NK cells, comprising two steps. In the first step, a population of cells with the ability to differentiate into NK cells, such as hematopoietic stem cells or hematopoietic progenitor cells, is seeded in a first medium comprising IL-15 and, optionally, other factors, so that the population expands, partially differentiating into NK cells. In the second step, the cells from the first step are expanded in a second medium comprising IL-2 to produce a population of activated NK cells, called TSNK cells, which are used to suppress the proliferation of tumor cells, treat viral infections, or treat cancer, such as blood cancers and solid tumors. This reference provides background information on the concentrations of the expansion and activation factors used to obtain the aforementioned TSNK cells.

[0016] Despite all these advances in adoptive cell therapy, immunosuppressive TME and toxicity still restrict the clinical application of these therapies, essentially because NK cells lose their cytotoxic capacity against tumor cells over time, therefore, therapeutic strategies that improve their effectiveness and safety are still required.

[0017] SUMMARY OF THE INVENTION

[0018] With the aim of overcoming the shortcomings of the previous technique, the present invention proposes a method for the activation and expansion of NK cells “ex vivo”, said method comprising the steps of: i. providing a culture of NK cells;

[0019] i. add to said NK cell culture an ectonucleotidase inhibitor, preferably CD39 (NTPDasal), selected from the group consisting of ARL67156, PSB 069, Suramin, 8-BuS-ATP, BG0136, POM-1, POM-5, SBT-C1, SBT-C6, or combinations thereof;

[0020] iii. after 10 minutes perform a first activation of the NK cells in culture, preferably using IL-2, or alternatively, a cytokine selected from the group consisting of IL-2, IL-7, IL-9, IL-15, IL-21 and TNFα, or a combination of these;

[0021] iv. In a second phase, perform a second activation and expansion of cultured NK cells using a cytokine or growth factor selected from the group consisting of IL-2, IL-7, IL-12, IL-15, IL-18, IL-21, IFN-γ, IFN-γ, TNF-α, IL-10, activating receptor ligands, feeder cells, or a combination thereof.

[0022] In a preferred embodiment of the invention, the CD39 inhibitor called ARL67156 is used as an ectonucleotidase inhibitor, which is preferably used at a concentration between 100 and 200 pM and more preferably at 80 pM, and is left for 10 to 15 minutes before adding the activating stimulus.

[0023] In another embodiment of the method of the invention, the first activation of NK cells is performed for 4 days using IL-2 in a preferred concentration range of between 500 and 2000 Ul / ml.

[0024] In yet another preferred embodiment of the invention, the second phase of NK cell activation and expansion is performed by changing the medium and incubating the cells for 4 days with IL-2 at a preferred concentration range of between 500 and 2000 U / mL and more preferably 1000 IU / mL; followed by changing the medium and incubating for 4 days in the presence of IL-15 at a preferred concentration range of between 5 and 20 nM and more preferably 10 nM.

[0025] Another object of the present invention is the cultured and expanded NK cells, using the method described for the activation and expansion of NK cells “ex vivo”, which show 21.8% cytotoxicity on muhno B16F10 melanoma cells, compared to 6.3% cytotoxicity shown by IL-2-activated cells without the CD39 inhibitor, and which also produce a release of IFN-γ into the extracellular medium twice as much as NK cells activated only with IL-2.

[0026] BRIEF DESCRIPTION OF THE FIGURES

[0027] Figure 1. ATP release into the extracellular medium induced by IL-2 in NK cells. The kinetics of ATP release after stimulation with IL-2 (2000 IU / mL) are shown, reaching a maximum during the first minute of activation, as well as the dependence of the phenomenon on the concentration of IL-2.

[0028] Figure 2. Participation of the Pannexin-1 channel in IL-2-induced ATP release. It is evident that the use of the specific inhibitor 10Panx significantly reduces the concentration of ATP in the extracellular medium, indicating that the release depends on the activation of Pannexin-1.

[0029] Figure 3. Effect of CD39 inhibition on extracellular ATP concentration in IL-2-activated NK cells. Treatment with ARL67156 prevents the degradation of released ATP, maintaining high levels in the extracellular medium.

[0030] Figure 4. Expression of genes related to mitochondrial metabolism induced by ATP released via Pannexin-1. It is shown that inhibition of the channel with 10Panx reduces the expression of PGC1a and Tfam, implying that this signaling regulates mitochondrial biogenesis.

[0031] Figure 5. Increase in gene expression induced by CD39 inhibition in the presence of IL-2. It is observed that treatment with ARL67156 increases the expression of PGC1a and CD71, genes associated with energy metabolism and cell proliferation.

[0032] Figure 6. Regulation of effector genes by purinergic signaling in NK cells. Inhibition of Pannexin-1 reduces the expression of IFNγ, perfohna, and granzyme B after IL-2 stimulation, indicating a direct role of released ATP in the induction of effector functions. Figure 7. Decreased cytotoxic activity by inhibition of ATP release in IL-2-activated NK cells. Treatment with 10Panx reduces B16F10 cell lysis, indicating that purinergic signaling is necessary to achieve optimal cytotoxicity.

[0033] Figure 8. Experimental scheme of the ex vivo NK cell activation protocols used in the functional and gene expression examples (P1 to P5). Protocol P2 represents the preferred embodiment of the invention.

[0034] Figure 9. Increased expression of metabolic genes in NK cells activated with the P2 protocol. A higher relative expression of PGC1 a, Tfam, cMyc, CD98 and CD71 is observed, compared to control protocols, indicating a more metabolically active phenotype.

[0035] Figure 10. Oxidative metabolic profile induced by the P2 protocol. It shows that NK cells treated with P2 exhibit lower L-lactate secretion, along with greater mitochondrial mass and potential, indicating a preference for oxidative metabolism.

[0036] Figure 11. IFNy gene expression in NK cells activated according to different protocols. Activation with P2 generates significantly higher expression than controls, comparable only to the IL-15 (P5) based protocol.

[0037] Figure 12. IFNy secretion measured in culture supernatants. NK cells activated with the P2 protocol show the highest levels of secretion of this cytokine, confirming their functional activation.

[0038] Figure 13. Cytotoxic activity of NK cells against B16F10 cells after activation with different protocols. Cells activated with P2 exhibit the greatest lytic capacity, superior to that observed with other treatments.

[0039] Figure 14. Evaluation of functional recovery capacity after contact with tumor cells. NK cells activated with P2 and previously exposed to B16F10 cells maintain high cytotoxic activity after 18 hours of rest, indicating improved functional persistence. DETAILED DESCRIPTION OF THE INVENTION

[0040] It is important to consider that many strategies for adoptive NK cell therapy have focused primarily on achieving high cell expansion and high cytotoxic activity; however, a major challenge in current immunotherapy is ensuring that the high functional activity of NK cells is sustained over time. This is addressed in the present invention by promoting the differentiation of these NK cells toward a phenotype with an improved metabolic profile. To this end, a staged activation of these cells was designed, where the first stage aims to enhance mitochondrial metabolism, followed by a second stage that generates cell expansion and functional potentiation.

[0041] With this objective, the inventors designed a method for activating NK cells, in which the signaling pathway mediated by the release of ATP induced by interleukin 2 (IL-2) in NK cells is activated, resulting in an increase in mitochondrial metabolism, making it possible to metabolically sustain the stimulation with other cytokines that induce the expression of effector molecules, such as IL-15; thus, the NK cells activated with the method of the invention exhibit high functionality along with a greater metabolic capacity, sustained over time.

[0042] In this invention, the impact of enhancing the activation of the signaling pathway mediated by ATP released in response to IL-2, using an inhibitor of the ectoATPase CD39 (NTPDasel), on the metabolism of NK cells was also evaluated, in terms of improving the functionality and cytotoxic response of said NK cells to stimulation with cytokines such as IL-15, optimizing their antitumor capacity ex vivo, for a longer time.

[0043] This application relates to obtaining a population of activated Natural Killer (NK) cells, characterized by increased functionality, improved cytotoxic capacity, and sustained IFN-γ release, and to the method used to optimize the ex vivo antitumor capacity of these NK cells by improving their cytotoxic capacity and IFN-γ release. To carry out the NK cell activation of the present invention, an NK cell activation method was designed that uses various interleukins, preferably interleukins selected from the group consisting of IL-2, IL-12, IL-18, IL-21, and IFNα; IL-15. In a preferred embodiment, the interleukins used in the method of the present invention are IL-2 and IL-15.

[0044] It is known that once ATP is in the extracellular medium, it is metabolized by the action of ectoATPases, of which CD39 (belonging to the E-NTPDase family and expressed in immune cells) present on the cell surface catalyzes the sequential dephosphorylation of ATP to adenosine monophosphate (AMP), and finally CD73 hydrolyzes AMP to adenosine [Allard, 2017]. Therefore, in the NK cell activation method of the invention, an inhibition step of the intracellular ATPase with CD39 is included to slow down the hydrolysis of extracellular ATP, during the activation of NK cells with IL-2, to subject them to a subsequent activation step with IL-15.

[0045] During the development of the NK cell activation method of the present invention, it was established that the amount of IL-2 to be used in the activation of NK cells is between 500 and 2000 IU / mL of culture. In a preferred embodiment, the amount of IL-2 is selected from 500, 1000, 1500, or 2000 IU / mL of IL-2 culture. In a more preferred embodiment of the invention, the amount of IL-2 in said NK cell culture is 1000 IU / mL. In a preferred embodiment, the NK cells of the invention are stimulated with IL-2 after they have been exposed for a period of time to the action of the ectoATPase inhibitor CD39.

[0046] The first phase or stage of NK cell activation of the invention begins once these cells have been subjected to CD39 inhibition for an exposure time of between 0 and 120 minutes. Preferably, the exposure time of the NK cells to the CD39 inhibitor is selected from 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, and 50 minutes. In a preferred embodiment, the CD39 inhibition is carried out for 10 or 15 minutes. In a more preferred embodiment, the CD39 inhibition is carried out for 15 minutes. For this stage, the CD39 inhibitor is selected from the group of CD39 inhibitors consisting of: PSB 069, Suramin, ARL67156, 8-BuS-ATP, BG0136, POM-1, POM-5, SBT-C1, SBT-C6 and anti-CD39 antibodies that inhibit its activity; in a preferred modality, the CD39 inhibitor is ARL67156.

[0047] In a preferred embodiment of the invention, a culture of NK cells is initially subjected to the action of the inhibitor ARL67156, which inhibits the CD39 ectoATPase of these cells, to continue their activation in the presence of IL-2, in a sequence of consecutive steps, including an additional activation step with IL-2 alone, concluding with a final activation step with IL-15. This specifically designed sequence of steps allows obtaining the activated NK cells of the invention that also exhibit sustained cytotoxic activity over time.

[0048] As explained, the present invention relates to a method for producing ex vivo activated NK cells, characterized by enhanced metabolism and increased functional capacity for IFNγ secretion and cytotoxic activity. This method comprises a first metabolic activation phase using high concentrations of IL-2 capable of inducing the release of ATP into the extracellular medium, in conjunction with the inhibition of the hydrolysis of the secreted ATP to enhance a signaling pathway mediated by this released ATP, which regulates the mitochondrial metabolism of NK cells. In a preferred embodiment, purified NK cells are cultured in the presence of an ectoATPase inhibitor CD39, and then IL-2 is added to a final concentration of between 500 and 2000 U / mL for 4 days.The second phase consists of activation and functional expansion using additional factors that allow for the proliferation of NK cells and an increase in functional activity. In a preferred embodiment of the invention, the cells activated in the first activation phase are incubated with IL-2 at a final concentration of between 500 and 2000 U / mL for an additional 4 days and then incubated with IL-15 for an additional 4 days, among other possible stimuli.

[0049] The present invention can be used to generate a population of NK cells with high functionality and sustained by increased energy metabolism, which can be used in cell transplantation, in adoptive immunotherapies with autologous and allogeneic cells, for the genetic modification of NK cells, and in combination with other therapeutic and sensitizing agents for the treatment of cancer and other diseases. The present invention is based on the finding that IL-2 induces the release of ATP into the extracellular environment in NK cells ex vivo. To determine this essential step of the method of the invention, the timing of ATP release in response to IL-2 was first analyzed (Figure 1A), as well as the concentrations at which IL-2 induces ATP release (Figure 1B), the mechanism by which this release into the extracellular environment occurs (Figure 2), and whether CD39 participates in the hydrolysis of ATP in the extracellular environment (Figure 3).Markers of the metabolic phenotype developed by NK cells by ATP release in response to IL-2 were then analyzed using a pannexin-1 channel inhibitor (Figures 4A and 4B), as was the effect of inhibiting the hydrolysis of released ATP using a CD39 inhibitor during IL-2 activation of NK cells (Figures 5A and 5B). The effect of IL-2-induced ATP release on the functional phenotype of NK cells was analyzed by the relative quantification of transcripts for IFN-γ, perforin, and granzyme B (Figures 6A, 6B, and 6C) and by the cytotoxic activity of NK cells on muhno B16F10 melanoma cells (Figure 7).

[0050] The NK cells used for this invention can be obtained from various tissues such as spleen, peripheral blood, tissue residents, tumor infiltrators, or differentiated from hematopoietic stem cells or precursors present in tissues, for example, in bone marrow, cord blood, or others.

[0051] The present invention is carried out in a liquid cell culture medium, where any known cell culture medium may be used, including synthetic media, media with special supplements, serum derivatives, plasma, or combinations thereof. As used herein, the culture includes providing all the physical and chemical conditions necessary for the maintenance, activation, and proliferation of NK cells ex vivo and for their subsequent in vivo use.

[0052] Inhibition of ATP hydrolysis can be achieved using CD39 inhibitors (NTPDases), and optionally one or more inhibitors of other members of the ecto-NTPDase family (such as NTPDase2, NTPDase3, and NTPDase8), an inhibitor of the ecto-nucleotide pyrophosphatase / phosphodiesterase (ENPP) family, and an alkaline phosphatase inhibitor. These inhibitors can be small molecules or antibodies that inhibit the activity of these enzymes. In a preferred embodiment, CD39 is inhibited using 100 pM of ARL67156, but others such as PSB 069, Suramin, ARL67156, 8-BuS-ATP, BG0136, POM-1, POM-5, SBT-C1, SBT-C6, or combinations thereof can be used. These are added to the liquid culture medium within a time range of 0 (simultaneously) to 120 minutes before adding IL-2. In a preferred embodiment, this is added between 10 and 15 minutes before adding IL-2, and more preferably, 15 minutes before.

[0053] The concentration of IL-2 in the liquid culture medium is in the range of 500 to 2000 IU / mL. For IL-2, the standard International Unit (IU) used in this invention is determined by its ability to induce CTLL-2 cell proliferation. In a preferred embodiment, the optimum concentration is chosen between 1000 and 2000 IU / mL.

[0054] Alternatively to the use of IL-2, cytokines that use the ye chain (CD132) as part of their receptor can be used, namely: IL-15, IL-4, IL-7, IL-9, IL-15 and IL-21, or combinations of these.

[0055] In this first activation phase, the incubation of NK cells in the liquid culture medium with the CD39 and IL-2 inhibitor can be carried out for a period of between 1 hour and 5 days. Preferably, according to this invention, the incubation is carried out for a period of 3 to 4 days, and more preferably, 4 days.

[0056] In a second activation phase of the method of the present invention, IL-2-activated NK cells, in the presence of the CD39 inhibitor, are activated with a second stimulus that enhances their functionality and induces proliferation. Preferably, this second activation is carried out by incubating the NK cells in liquid culture medium with IL-2, which can be used in a range of 100 to 5000 IU / mL. Preferably, the IL-2 concentration ranges from 500 to 3000 IU / mL, more preferably from 1000 to 2000 IU / mL, with 1000 IU / mL being the most preferred concentration. The culture is then activated for 4 days, followed by an expansion of the NK cells for 4 days with 10 nM IL-15.

[0057] In this second activation-expansion phase, IL-15 can be used in a range of 0.1 to 50 nM. Preferably, the IL-15 concentration range is between 2 and 20 nM, more preferably in the range of 5 to 20 nM, and the most preferred concentration is 10 nM.

[0058] In the second phase of cell activation and expansion, NK cells can also be incubated with feeder cells, activating receptor ligands, other cytokines, and growth factors selected from IL-7, IL-12, IL-18, IL-21, IFN-α, IFN-γ, TNF-α, IL-10, or combinations thereof.

[0059] In the most preferred embodiment of the invention, the cells are incubated for 4 days with IL-2 and then 4 days with IL-15.

[0060] The incubation time in the second phase of activation-expansion of NK cells is in the range of 3 to 40 days, and in a preferred embodiment of this invention the total time of this second phase is 6 to 10 days, and more preferably 8 days.

[0061] A preferred embodiment of the invention consists of incubating purified NK cells in liquid culture medium in the presence of 100 pM of ARL67156 for 10 minutes and then adding IL-2 to a preferred final concentration of 1000 IU / mL, and maintaining the culture for 4 days, then renewing the culture medium and adding IL-2 to a preferred final concentration of 1000 IU / mL and culturing for 4 days, and finally renewing the culture medium again, adding IL-15 to a preferred final concentration of 10 nM and culturing for 4 days, until a total of 12 days is completed.

[0062] The population of NK cells activated according to the preferred form of the invention is characterized by having a high expression of selected metabolism-related genes: PGC1-a, TFAM, CD98 (SLC3A2), CD71 and c-MYC; increased mitochondrial mass and mitochondrial membrane potential and decreased lactate secretion, as indicators of lower glycolytic metabolism and greater mitochondrial function.

[0063] In one aspect of the invention, the NK cells activated according to the preferred embodiment are functionally characterized by significantly higher expression of IFNγ transcripts and IFNγ secretion into the extracellular medium than cells activated without CD39 inhibition and with no significant differences when activated with IL-15 alone for 12 days. According to another aspect of the embodiment, the NK cells activated according to the preferred embodiment are functionally characterized by having cytotoxic capacity against muhno B16F10 melanoma cells when placed in contact for 4 hours, compared to cells activated without the CD39 inhibitor in the first phase, or using the inhibitor in the second activation phase, or with IL-2 alone or with IL-15 alone for 12 days.

[0064] In another aspect of the embodiment, the NK cells activated according to the preferred form of the invention are characterized by performing cytotoxic activity for 4 hours against B16F10 cells and after 18 hours of being maintained in the culture medium, they exhibit the highest cytotoxic activity when confronted again with B16F10 cells.

[0065] According to another aspect of this embodiment, the invention provides a clinically relevant NK lymphocyte population composition for use in medical treatments, particularly for the treatment and prevention of: infectious diseases, autoimmune diseases, cancer, or preventively, for the elimination of senescent cells in the body.

[0066] In this aspect of implementation, the NK cell population can be used as immunotherapy on its own, or alternatively, it can be genetically modified to generate CAR-NK cells for use as immunotherapy.In an alternative form of use of the invention as immunotherapy, the cells can be combined with other cell immunotherapies and / or with sensitizing agents, such as checkpoint antibodies such as anti-PD-1, anti-PD-L1, anti-CTLA-4, anti-LAG-3, anti-TIGIT, anti-TIM-3, among others; and sensitizing agents such as: chemotherapeutic agents (e.g., carboplatin, paclitaxel, cyclophosphamide, vinchstin, dacarbazine, fludarabine), tyrosine kinase inhibitors (e.g., lenvatinib, cabozantinib, axitinib), epigenetic agents (e.g., azacitidine), metabolic agents such as IDO1 (indolamine 2,3-dioxygenase 1) inhibitors (e.g., epacadostat), tumor vaccines and oncolytic viruses (e.g., T-VEC) and radiotherapy; or combinations of these.EXAMPLES OF IMPLEMENTATION:.

[0067] The following are experimental examples illustrating preferred embodiments of the invention. These examples should not be interpreted as limiting, but rather as demonstrating different applications of the proposed protocol. The described procedures include both the analysis of the molecular mechanisms involved in NK cell activation by IL-2 and the development of a two-phase activation protocol that incorporates the inhibition of the CD39 ectoATPase in an initial phase to enhance the metabolic and functional profile of ex vivo activated NK cells.

[0068] Example 1. Experimental procedures for examples 2-5 Purification of NK cells from C57BL / 6 mice

[0069] NK cells were purified from male and female C57BL / 6 mice, aged 8–12 weeks. The animals were euthanized by cervical dislocation, and the spleens were removed under sterile conditions. The organs were mechanically disaggregated to obtain a splenocyte suspension, which was then centrifuged using Lymphocyte Separation Medium (Cellgro, Mediatech, VA, USA) to isolate mononuclear cells.

[0070] The cells obtained were maintained in RPMI 1640 medium (Invitrogen, Thermo Fisher) supplemented with L-glutamine (2 mM), 10% heat-inactivated fetal bovine serum (FBS), and antibiotics (50 U / ml penicillin and 50 pg / mL streptomycin), hereafter referred to as complete RPMI medium. To enrich the infoid I population, the cells were incubated for 2 hours at 37 °C with 5% CO2, allowing monocyte adhesion and separation of non-adherent cells.

[0071] NK cells were purified from this population using the NK Cell Isolation Kit (Miltenyi Biotech), following the manufacturer's instructions. The purity of the NK cells obtained (CD37NK1,1 + ) was greater than 95%, according to analysis by flow cytometry. Quantification of extracellular ATP.

[0072] To analyze ATP release by NK cells in response to IL-2, 1.5 x 10 5 Cells per well in 96-well plates, in 100 pL of complete RPMI medium. Stimulation was performed by adding an additional 100 pL of RPMI medium with IL-2 (PeproTech, ThermoFisher) at double the concentration, to reach the final desired concentration.

[0073] The following were evaluated:

[0074] (i) the ATP release kinetics (0 to 615 seconds) using IL-2 at 2000 IU / mL,

[0075] (i) concentration dependence (0, 100, 500, 1000 and 2000 IU / mL), and ATP was quantified in the supernatant after 30 seconds of stimulation.

[0076] (iii) Pannexin-1 participation was determined by pre-incubation with the inhibitory peptide 10Panx (100 pM) (R&D System, Bio-Techne) or scramble peptide (R&D System, Bio-Techne) as a control. ATP quantification in the supernatant was performed 30 seconds after stimulation with IL-2 (2000 IU / ml).

[0077] (iv) The effect of CD39 inhibition using ARL67156 (Santa Cruz Biotechnology) (200 pM) in conjunction with IL-2 (2000 Ul / ml). Cells stimulated only with IL-2 (2000 Ul / ml) were used as a control. ATP quantification in the supernatant was performed after 0, 1, 5, and 10 minutes of stimulation.

[0078] The supernatants were collected at the indicated times and stored at -80 °C until analysis. ATP quantification was performed using the “ATP Determination Kit” (Invitrogen, Thermo Fisher), based on the luciferase-luciferin reaction, measuring luminescence on an Infinite® 200 Pro M Plex reader (Tecan).

[0079] Ex vivo activation of NK cells, using cytokines and inhibitors.

[0080] The study of the effect of IL-2-induced ATP release on the expression of genes related to NK cell metabolism and function was performed 72 hours after activation with 2000 IU / mL of IL-2 in RPMI 1640 complete medium. To inhibit ATP release in response to IL-2, the peptide 10Panx was used, and the peptide scramble (ser) was used as a control, both at a concentration of 100 pM. To inhibit ATP hydrolysis in the extracellular medium and promote ATP signaling, the ectoATPase inhibitor CD39 (NTPDasal) ARL67156 (100 pM) (Santa Cruz Biotechnology) was used. In all experiments, the inhibitor was added 15 minutes before IL-2 administration and remained present throughout the 72-hour incubation period.

[0081] RNA isolation and cDNA synthesis.

[0082] Following stimulation, supernatants were collected for IFNγ analysis by ELISA, and cells were processed for total RNA isolation using the EZNA® Total RNA Kit I (Omega Bio-Tek). RNA integrity was assessed by electrophoresis and purity by absorbance at 260 / 280 nm. cDNA synthesis was performed using RevertAid Reverse Transcriptase (Thermo Scientific) with oligo dT, following the manufacturer's protocol.

[0083] Real-time polymerase chain reaction (qPCR)

[0084] Transcript quantification was performed by qPCR using the KAPA SYBR® FAST Universal qPCR reagent (Kapa Biosystems, Merck) and an AriaMX RT-PCR instrument (Agilent Technologies). The reactions included 5 pL of KAPASYBR®, 0.3 pL of forward primer, 0.3 pL of reverse primer, and cDNA plus nuclease-free water to a total of 10 pL of reaction mixture. The thermal program included 3 minutes of initial activation, followed by 40 cycles of: 3 seconds at 95 °C for strand separation, then 20 seconds at the primer hybridization temperature (between 55 and 60 °C), followed by 15 seconds of elongation; and finally, product dissociation analysis by gradual temperature increase and fluorescence measurement.

[0085] Table 1. The sequences used for the amplification of relevant genes in NK cells (metabolic and effector). Gene Sequence

[0086] Forward starter Reverse starter

[0087] GRANB ACTCTTGACGCTGGGACCTA AGTGGGGCTTGACTTCATGT CD71 GGCGCTTCCTAGTACTCCCT TCTGCAGCCAGTTTCATCTCCA PERF CCGGGGATTGTTATTGTTCC AGCCCCTGCACACATTACTG

[0088] cMYC GCGTTGGAAACCCCGACAG CTTCCAGATATCCTCACTGGGC TFAM GGGAATGTGGAGCGTGCTAA TGATAGACGAGGGGATGCGA PGC1a GTGTTCTGGTACCCAAGGCA GGAGACTGGGCCGTTTAGTC SLC7A5 CTTCGGCTCTGTCAATGGCCGTTGTC (CD98)

[0089] IFNy GCTTTAACAGCAGGCCAGAC GCACCAGGTGTCAAGTCTCT

[0090]

[0091] Cytotoxicity Assay.

[0092] B16F10 cells were labeled with calcein-AM (Invitrogen, Thermo Fisher) (2 pM, 30 minutes, 37 °C) and co-cultured with activated NK cells (E:B ratio = 5:1) in a 96-well round-bottom plate for 4 hours at 37 °C. The plate was then centrifuged, and the fluorescence intensity (excitation 495 nm, emission 515 nm) was measured from 100 µL of the supernatant. The percentage of cytotoxicity was calculated based on the release of cytotoxicity compared to spontaneous lysis controls and maximum lysis (Triton X-100 10%) shown by the labeled B16F10 cells for each experiment.

[0093] Example 2. Analysis of the mechanism of ATP release to the extracellular medium induced by IL-2 in NK cells.

[0094] In this example, the release of ATP by NK cells in response to stimulation with IL-2 was evaluated, as well as the mechanisms involved in this release and its subsequent degradation in the extracellular environment.

[0095] To analyze the release kinetics, purified NK cells were stimulated with IL-2 at a concentration of 2000 IU / mL, and the ATP concentration in the extracellular medium was quantified at different time points after stimulation. The results (Figure 1A) showed that ATP release occurs rapidly and transiently, peaking between 15 and 45 seconds after stimulation and returning to baseline levels between 5 and 10 minutes. Subsequently, the dependence of this response on IL-2 concentration was examined. To do this, NK cells were stimulated with IL-2 at concentrations of 0, 100, 500, 1000, and 2000 IU / mL for 30 seconds. Significant ATP release was observed starting at 500 IU / mL, with a maximum response at 2000 IU / mL (Figure 1B).

[0096] Several mechanisms for releasing ATP into the extracellular space have been described, including vesicle exocytosis and the opening of membrane channels. Among the latter, the Pannexin-1 channel has been identified in various cells of the immune system and has been associated with processes such as T lymphocyte activation and the inflammasome in macrophages. Pannexin-1 activation allows for the rapid release of ATP in response to mechanical stimuli and biochemical signals. Although Pannexin-1 and purinergic receptors have been described in NK cells, their specific functions in this cell type are not fully understood.

[0097] To determine whether IL-2-induced ATP release depends on Pannexin-1, the specific inhibitory peptide 10Panx was used. A structurally similar scramble peptide (ser) without inhibitory activity was used as a negative control. NK cells were pre-incubated for 15 minutes with either 10Panx or ser, and then stimulated with IL-2 (2000 IU / mL) for 30 seconds. The results showed that treatment with 10Panx significantly inhibited IL-2-induced ATP release (Figure 2), indicating that Pannexin-1 mediates this process. This mechanism of rapid IL-2-induced ATP release has not been previously described in NK cells, representing a novel finding in the context of their immune activation.

[0098] Once released, ATP can act as an auto- or para-signal by activating purinergic receptors, which are widely expressed on immune system cells, including NK cells. However, this signaling is transient, as ATP is rapidly degraded by ectonucleotidases. In particular, the ectoATPase CD39 catalyzes the conversion of ATP to ADP and then to AMP, while CD73 transforms AMP into adenosine, a molecule with immunosuppressive properties. To analyze the role of CD39 in the degradation of released ATP, the inhibitor ARL67156, which is highly selective for this enzyme, was used. NK cells were stimulated with IL-2 (2000 IU / mL) in the presence or absence of ARL67156 (200 pM), and the concentration of ATP in the extracellular medium was quantified at 0, 1, 5, and 10 minutes post-stimulation. The results showed that, in the absence of the inhibitor, extracellular ATP rapidly decreases to basal levels.In contrast, in the presence of ARL67156, the released ATP remained significantly elevated (Figure 3), indicating that CD39 actively participates in its hydrolysis.

[0099] Example 3. Analysis of the effect of IL-2-induced ATP release in NK cells on the expression of genes related to mitochondrial metabolism.

[0100] In this example, the impact of IL-2-induced ATP release on the expression of key mitochondrial genes in NK cells was evaluated, which have previously been associated with effector functions and the regulation of cellular metabolism.

[0101] Two experimental strategies were used for this purpose. The first was to inhibit ATP release using the Pannexin-1 channel inhibitor, 10Panx (Figures 4, 6, and 7), and the second was to decrease the rate of degradation of released ATP by inhibiting the acto-ATPase CD39 with ARL67156 (Figure 5). The objective of this second strategy was to prolong the presence of ATP in the extracellular medium in order to enhance signaling mediated by this molecule.

[0102] Previous results from the team of inventors had shown that activation of NK cells with IL-2 (2000 IU / mL) for 72 hours induces an increase in both mitochondrial mass and mitochondrial membrane potential. These changes correlate with an increase in the expression of the transcriptional coactivator PGC1α, a master regulator of mitochondrial biogenesis. The results of the present experiment indicated that inhibition of ATP release with 10Panx blocked the increase in the expression of PGC1α (Figure 4A) and of Tfam (Figure 4B), the latter being an essential factor for mitochondrial DNA transcription and replication, and whose expression is regulated by PGC1α.

[0103] In contrast, when NK cells were activated with IL-2 in the presence of ARL67156, a further increase in the expression of PGC1a (Figure 5A) and the transferrin receptor CD71, involved in iron transport necessary for mitochondrial processes, was observed. These findings support the role of purinergic signaling in the regulation of mitochondrial metabolism in ex vivo-activated NK cells.

[0104] Example 4. Effect of IL-2-induced purinergic signaling on effector gene expression and cytotoxic activity of NK cells.

[0105] This example focused on determining whether the release of ATP in response to IL-2 influences the expression of genes related to effector functions and the cytotoxic activity of NK cells.

[0106] The expression of the IFNy, perfohna, and granzyme B genes was analyzed in IL-2-activated NK cells (2000 IU / mL for 72 hours) in the presence or absence of the inhibitor 10Panx. In all cases, Pannexin-1 inhibition significantly reduced the expression of these genes (Figure 6), indicating that extracellular ATP-induced signaling contributes to their regulation.

[0107] Additionally, the in vitro cytotoxic activity of NK cells was evaluated against the muhna B16F10 tumor cell line, known for its low sensitivity to lysis mediated by non-activated NK cells. IL-2-stimulated NK cells exhibited significantly increased cytotoxicity, which was inhibited by 10Panx treatment during activation (Figure 7).

[0108] These results demonstrate that purinergic signaling mediated by ATP release through the Pannexin-1 channel in response to IL-2 not only enhances the expression of effector genes but is also necessary for the development of robust cytotoxic activity in ex vivo activated NK cells. Example 5. Experimental procedures for examples 6-7

[0109] The following examples were designed based on previously obtained results, with the aim of inducing sustained functional activity in NK cells by enhancing their cellular metabolism. To achieve this, a two-phase activation scheme was developed: the first phase focused on enhancing mitochondrial metabolism, and the second on inducing cell expansion and strengthening effector functions.

[0110] The strategy is based on the pharmacological inhibition of ATP hydrolysis by NK cells in response to IL-2, thereby enhancing their puhnergic signaling and improving the metabolic and functional profile of the cells. The experimental procedures used in Examples 6 and 7 are described below, illustrating the effects of the preferred protocol of the invention (P2) compared to various controls.

[0111] Activation and ex vivo expansion protocols of NK cells.

[0112] Purified NK cells were used, which were cultured in quantities of 1x10 5Cells per well were incubated following the stimulation protocols described in Figure 8, where P2 is the preferred activation scheme of the invention and the other protocols were developed as controls to exemplify the improvements in metabolism and function of the NK cells obtained. All incubations were performed in complete RPMI medium, as described in Example 1, with medium changes every 4 days and maintained under standard culture conditions (high humidity, 5% CO2 and 37 °C).

[0113] In the first activation phase, NK cells following protocols P1, P2, P3, and P4 were incubated with 1000 IU / mL of IL-2, while cells activated according to protocol P5 were activated with 10 nM of IL-5, all for 4 days. In the case of P2, NK cells were pre-incubated with ARL67156 (100 pM) for 15 min, and then IL-2 was added. The second phase then begins, in which half of the culture medium is removed and replaced with fresh RPMI complete medium, and the cytokine is added to maintain the same concentration as before, for 4 days. In the case of P3, ARL67156 (100 pM) was added for 15 min, and then IL-2 (1000 IU / mL) was added. After the 4 days are completed, half of the culture medium is replaced and IL-2 (1000 IU / mL) is added for P1 and 10 nM of IL-15 for the rest of the protocols and they are left for an additional 4 days.Figure 8 shows a diagram with the cytokine used every 4 days and when the CD39 inhibitor is used.

[0114] At the end of day 12, the cells were collected by centrifugation (1500 rpm, 5 minutes). The supernatants were stored at -80 °C for IFNγ secretion analysis. The cell pellets were washed twice with PBS for subsequent RNA extraction, cDNA synthesis, and gene expression analysis by qPCR, as described in Example 1.

[0115] Quantification of secreted IFNy.

[0116] Culture supernatants were analyzed after 12 days of stimulation using the “Mouse IFNy gamma Uncoated ELISA” kit (Invitrogen, Thermo Fisher). 100 pL of supernatant were deposited per well (in duplicate) onto a plate previously sensitized with the IFNy capture antibody. Quantification was performed by measuring absorbance at 450 nm, following the manufacturer's instructions.

[0117] Quantification of L-lactate.

[0118] To estimate the glycolytic flux of NK cells after activation, the L-lactate concentration in the supernatant of activated cell cultures was quantified according to the protocols described above. The Lactate Assay Kit (BioAssay System) was used for this purpose, following the manufacturer's recommendations. In a 96-well plate, 20 pL of supernatant was mixed with 80 pL of the working reagent provided by the kit, and the absorbance was then measured at 565 nm. Analysis of mitochondrial mass and mitochondrial membrane potential was also performed.

[0119] In addition, to estimate the mitochondrial mass of the NK cells treated with the protocols, 1x10 were labeled 5Cells were incubated with 50 nM Mitotracker® Green FM (Invitrogen, Thermo Fisher) for 30 min at 37 °C. For cytofluorometric analysis of mitochondrial membrane potential, the JC-1 probe (Invitrogen, Thermo Fisher) was used at a concentration of 6 ng / mL, and the cells were incubated for 15 min at 37 °C. In both cases, after probe labeling, the cells were washed and resuspended in cold PBS for subsequent analysis by flow cytometry. The analysis was performed using a Canto II FACS (Becton-Dickinson) and FlowJo™ software. The FL2 / FL1 fluorescence ratio (red / green) was used for mitochondrial membrane potential analysis.

[0120] Cytotoxicity assay and functional recovery assessment.

[0121] The cytotoxic activity of NK cells was assessed according to the procedure described in Example 1, using calcein-AM-labeled B16F10 cells as target cells. To analyze functional recovery capacity, previously activated NK cells were incubated with unlabeled B16F10 cells for 4 hours at an effector-to-target ratio of 5:1. Subsequently, the NK cells were recovered and cultured in complete medium without cytokines for 18 hours.

[0122] After this time, a second cytotoxicity assay was performed using calcein-AM labeled B16F10 cells, in an effector:target ratio of 1:1. The percentage of cytotoxicity was determined based on fluorescence release, as described in the standardized protocol.

[0123] Example 6. Evaluation of the induced metabolic phenotype in ex vivo activated NK cells using a protocol (P2) that includes inhibition of CD39 activity during an initial activation phase with IL-2.

[0124] This example evaluates the impact of the P2 activation protocol on the metabolic profile of NK cells, with the aim of determining whether this strategy promotes a phenotype associated with greater sustained functional capacity.

[0125] NK cells were activated using the previously described P2 protocol (Figure 8), which includes a first phase with inhibition of CD39 activity using ARL67156 during IL-2 stimulation, followed by a second functional expansion phase with IL-2 and IL-15. This protocol was compared with control protocols (P1, P3, P4, and P5) that vary in the presence of the CD39 inhibitor and in the type of cytokine used during the first activation phase and / or the second phase.

[0126] The expression of genes relevant to mitochondrial metabolism and NK cell function was analyzed, revealing that cells treated with the P2 protocol exhibited higher relative expression of PGC1α, Tfam, cMyc, CD98, and CD71 (Figures 9A-E). These genes are involved in mitochondrial biogenesis, nutrient transport, and proliferation, and are associated with a more metabolically competent profile, as described in the literature.

[0127] Additionally, functional parameters of cellular metabolism were evaluated: L-lactate secretion, as a marker of glycolytic metabolism; mitochondrial mass; and mitochondrial membrane potential, as indicators of mitochondrial oxidative activity. The results demonstrated that the P2 protocol induces a metabolic profile characterized by lower L-lactate secretion (Figure 10A), along with greater mitochondrial mass (Figure 10B) and mitochondrial membrane potential (Figure 10C), compared to the control protocols. These findings suggest that pharmacological intervention on IL-2-induced signaling during the early activation phase favors the development of a phenotype with predominantly oxidative metabolism, consistent with greater functionality and persistence of NK cells.

[0128] The complete characterization of the functional effect, including IFNy secretion, cytotoxic activity, and post-cytotoxicity functional recovery, is described in the following examples.

[0129] Example 7. Functional evaluation of IFNy secretion and cytotoxic activity of ex vivo activated NK cells using a protocol with CD39 inhibition during initial activation with IL-2 (P2).

[0130] This example describes the functional effects of the P2 activation protocol on the secretory and cytotoxic capacity of ex vivo activated NK cells. The P2 protocol includes an initial activation phase with IL-2 in the presence of the CD39 inhibitor ARL67156, followed by additional stimulation phases with IL-2 and IL-15, as detailed in previous examples.

[0131] A central function of NK cells is the production of IFNγ, a key cytokine in the antitumor immune response. In this context, the relative expression of the IFNγ gene was evaluated by RT-qPCR at the end of the activation protocol. The results indicated that cells treated with protocol P2 showed a significant increase in IFNγ mRNA levels (Figure 11), higher than that observed in activated cells without inhibitor (P4) and comparable only to those treated exclusively with IL-15 (P5), which is known to strongly induce the expression of this cytokine. This result was consistent with the quantification of IFNγ secreted into the culture medium at the end of the 12-day protocol, measured by ELISA (Figure 12).NK cells activated under the P2 protocol showed significantly higher levels of IFNy secretion compared to the other protocols, confirming the effectiveness of the intervention on purinergic signaling to enhance this effector function.

[0132] To evaluate direct cytotoxic activity, the B16F10 melanoma cell line, characterized by its relative resistance to NK cell-mediated lysis, was used as a target. In 4-hour co-incubation assays (effector:target ratio of 5:1), NK cells treated under protocol P2 exhibited the highest cytotoxic activity against B16F10 among all groups analyzed (Figure 13). This activity was superior to that observed in inhibitor-free protocols (P1, P3, P4, and P5) and comparable only to optimally stimulated positive controls.

[0133] Additionally, the functional recovery capacity of NK cells was evaluated after a first round of cytotoxicity testing. To this end, NK cells activated according to the different protocols were incubated for 4 hours with B16F10 cells (1:1 ratio). Subsequently, they were rescued and maintained in cytokine-free culture for 18 hours, after which a new cytotoxicity assay was performed. NK cells treated with protocol P2 maintained a high residual cytotoxic capacity against B16F10 (Figure 14), in contrast to cells treated according to protocols P3, P4, and P5, which showed little or no lysis capacity under these conditions. Cells treated under protocol P1 retained some activity, although less than those treated with P2.

[0134] These results indicate that inhibiting CD39 during the initial IL-2 activation phase enhances not only the expression of genes associated with NK cell function, but also IFNγ secretion capacity and sustained cytotoxicity against tumor cells. This approach represents an effective strategy for optimizing NK cell function in adoptive immunotherapy protocols by promoting a more metabolically and functionally competent phenotype.

Claims

CLAIMS 1. Method for the activation of NK cells “ex vivo”, CHARACTERIZED in that it comprises the steps of: i. provide NK cells in a culture medium; i. adding to said NK cell culture, during an initial activation phase, a CD39 inhibitor or a functionally equivalent ectonucleotidase inhibitor with hydrolytic activity on extracellular ATP, in an amount effective to decrease the hydrolysis of extracellular ATP released by said cells; and iii. activate said NK cells using at least one cytokine from the ye family.

2. The method of claim 1, CHARACTERIZED in that the NK cells are obtained from tissues of selected organs from the group consisting of spleen, peripheral blood, tissue residents, tumor infiltrators, or cells differentiated from hematopoietic stem cells, precursors present in tissues such as bone marrow, umbilical cord blood, among others.

3. The method of claim 1, CHARACTERIZED in that the activation of NK cells is carried out with I L-2.

4. The method of claim 3, CHARACTERIZED in that the activation is carried out with IL-2 at a concentration between 500 and 2000 IU / mL for a period of time between 1 hour and 5 days.

5. The method of claim 4, CHARACTERIZED in that the activation is carried out with IL-2 at a concentration between 1000 and 2000 IU / mL and for a period of 3 to 4 days.

6. The method of claim 1, CHARACTERIZED in that the inhibitor is ARL67156.

7. The method of claim 6, CHARACTERIZED in that ARL67156 is at a concentration between 80 and 200 pM.

8. The method of claim 7, CHARACTERIZED in that ARL67156 is at a concentration of 100 pM.

9. The method of claim 1, CHARACTERIZED in that the NK cells, after the initial activation phase, undergo a second activation and / or expansion by means of “feeder” cells, activating receptor ligands, cytokines or growth factors selected from IL-2, IL-7, IL-9, IL-12, IL-15, IL-18, IL-21, IL-27, IFNNa, IFNp, TNFa, IL-10, or combinations thereof.

10. The method of claim 9, CHARACTERIZED in that the second activation and expansion of the NK cells is carried out with IL-2 at a concentration between 500 and 2000 IU / mL 4 days after the first activation.

11. The method of claim 10, CHARACTERIZED in that IL-2 is used at a concentration of 1000 IU / mL.

12. The method of any of claims 1 to 11, CHARACTERIZED in that after the second activation and expansion with IL-2, an expansion of the NK cells is carried out for 4 days with IL-15 at a concentration between 0.1 and 50 nM.

13. The method of claim 12, CHARACTERIZED in that IL-15 is at a concentration between 5 and 20 nM.

14. The method of claim 13, CHARACTERIZED in that IL-15 is at a concentration of 10 nM.

15. A population of activated NK cells obtainable by the method of any of claims 1 to 14.

16. The NK cell population of claim 15, CHARACTERIZED by having at least one of the following metabolic traits: increased mitochondrial mass, increased mitochondrial membrane potential, decreased lactate secretion, or increased expression of PGC1-α, TFAM, CD98 (SLC3A2), CD71 or c-MYC.

17. The NK cell population of claim 15 or 16, CHARACTERIZED by having greater cytotoxic capacity, greater expression and / or secretion of IFN-γ, or greater functional persistence compared to activated NK cells in the absence of the inhibitory agent of claim 1.

18. A pharmaceutical composition, CHARACTERIZED in that it comprises an NK cell population according to any of claims 15 to 17 and a pharmaceutically acceptable vehicle.

19. Use of an NK cell population according to any of claims 15 to 17, CHARACTERIZED in that said population serves for the preparation of a drug useful in the treatment and / or prevention of cancer, infectious diseases, autoimmune diseases or for the elimination of senescent cells in the body.

20. Method of treatment and / or prevention of cancer, infectious diseases, autoimmune diseases, or elimination of senescent cells in an individual, CHARACTERIZED in that it comprises administering to an individual in need a population of NK cells in accordance with claims 15 to 17.

21. The method according to claim 20, CHARACTERIZED in that said NK cell population is administered to the individual without genetic modification or after genetic modification of the NK cell population to generate CAR-NK.

22. The method according to any of claims 20 or 21, CHARACTERIZED in that said NK cell population is administered in combination with an additional therapy selected from cell immunotherapies, therapeutic antibodies, anti-infective agents, immunomodulatory agents, chemotherapeutic agents, tyrosine kinase inhibitors, epigenetic agents, metabolic agents, therapeutic vaccines, oncolytic viruses, radiotherapy, or combinations thereof.